Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.39 |
| ▸ | HTR3A | P46098 | 5/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242574 | 0.78 | CHRNA7 (0.40) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL3246098 | 0.78 | KCNH2 (0.47) | KCNH2 | |
| Hydrochloric Acid SCHEMBL3252642 | 0.77 | KCNH2 (0.46) | KCNH2 | |
| Hydrochloric Acid SCHEMBL3756715 | 0.77 | CHRNA7 (0.40) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL14694278 | 0.77 | DHFR (0.41) | CHRNA7 | |
| SCHEMBL5110025 | 0.76 | CHRNA7 (0.45) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL5112298 | 0.76 | HTR3A (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3242803 | 0.75 | MAPT (0.56) | — | |
| SCHEMBL2532555 | 0.74 | CHRNA7 (0.47) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL5116195 | 0.72 | HTR3A (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-8236793-B2 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NEUROSEARCH A/S (DK) | 2012-08-07 | — | — | US | disclosed |
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | ANIONA APS (DK) | 2010-05-06 | — | — | US | disclosed |
| EP-2172469-A1 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NeuroSearch A/S (DK) | 2010-04-07 | — | — | EP | disclosed |
| WO-2010026177-A1 | 1,4-DIAZA-BICYCLO [3.2.2] NONYL PYRIDINE DERIVATIVES AS NICOTINIC AND MONOAMINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2010-03-11 | — | — | WO | disclosed |
| US-7662808-B2 | N-[4-(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-phenyl]-benzamide; disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| EP-1713487-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2009-12-02 | — | — | EP | disclosed |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | ANIONA APS (DK) | 2008-09-18 | — | — | US | disclosed |
| EP-1713487-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005074940-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | GRIN2D 2046/4885GRIN3B 1622/4885GRIN1 940/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | GRIN2D 1067/4885GRIN3B 1196/4885GRIN1 1207/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | GRIN2D 2046/4885GRIN3B 1622/4885GRIN1 940/4885 |
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | CHRNA6, CHRNA10, CHRNA2 | GRIN2D 573/4885GRIN3B 271/4885GRIN1 427/4885 |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | CHRNA6, CHRNA10, CHRNA2 | GRIN2D 586/4885GRIN3B 282/4885GRIN1 440/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | GRIN2D 2204/4885GRIN3B 1726/4885GRIN1 1041/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | GRIN2D 2204/4885GRIN3B 1726/4885GRIN1 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.